and 5% to 7.5%, respectively (1) . The implication for widening the scope of those eligible for statins has been widely debated (3) (4) (5) .
Because the net benefit from treatment is directly proportional to the absolute risk (1), many of those newly eligible for statins will likely not accrue a large absolute reduction in risk from treatment. With a significant increase in the population eligible for treatment, accurate identification of low-risk statin candidates who are less likely to yield meaningful benefits is critical to facilitate appropriate resource allocation and shared decisionmaking processes.
Coronary artery calcium (CAC), detected by low radiation, noncontrast cardiac computed tomography testing, estimates the burden of coronary atherosclerosis and is a method for further risk stratification in the primary prevention setting (6, 7) . Increased CAC is associated with almost a 10-fold higher risk of adverse ASCVD events, independent of the baseline traditional risk profile (6, 7) . More importantly, the absence of CAC in an asymptomatic adult confers a very low risk for future cardiac events (8) (9) (10) (11) . This can potentially allow patient choices to focus on low-cost lifestyle modifications and the pursuit of flexible treatment goals.
In this study, we specifically aimed to determine the implications of the absence of CAC in reclassifying ASCVD risk such that many participants currently eligible for statin therapy move to a category in which the guideline no longer recommends treatment.
These results can have important implications for public health discussions aimed at improving the efficiency and cost-effectiveness of statin use in primary prevention settings. ported by contracts N01-HC-95159 through N01-HC-95169 from the National Heart, Lung, and Blood Institute. Dr. Nasir is on the advisory board for Quest Diagnostic; and is a consultant for Regeneron. Dr. Budoff is on the speakers bureau for General Electric.
METHODS
hypertension, current smoking, and history of diabetes mellitus, using the race-/sex-specific parameters from the ACC/AHA Pooled Cohort Equations with Hispanics/Chinese calculated as white (2) . CAC SCORE MEASUREMENTS. The MESA methods for computed tomography scanning and interpretation were published previously (13) . All participants were scanned twice, with mean CAC (Agatston) score used for all analyses (14) . Estimates of radiation dose determined according to the MESA protocol for a single scan obtained through the heart with the Imatron C150, Volume Zoom, and LightSpeed Pro 16 scanners were as follows: 0.6 and 0.7, 0.9 and 1.1, and 0.9 and 1.1 mSv for men and women, respectively (15) . Participants were told that they had no CAC or that it was less than average, average, or greater than average, and that they should discuss the results with their physicians.
ASCERTAINMENT OF ASCVD EVENTS. At intervals of 9 to 12 months, an interviewer contacted each Overall, 50% of the study population was recommended for moderate-to high-intensity statin, 12% was considered for statin, and 38% was not eligible for statin therapy. ASCVD ¼ atherosclerotic cardiovascular disease; LDL ¼ low-density lipoprotein. (59 AE 9 years, 47% males), among whom 2% (n ¼ 94) Values are mean AE SD or n (%).
BMI ¼ body mass index; CHD ¼ coronary heart disease; HDL-C ¼ high-density lipoprotein cholesterol; LDL-C ¼ low-density lipoprotein cholesterol. Nasir et al. According to the ACC/AHA guidelines, 38% (n ¼ 1,822) nondiabetic patients with LDL-C 70 to 189 mg/dl were eligible for moderate-to highintensity statins because of their 10-year estimated ASCVD risk $7.5% ( Figure 1) . As a result, in total, 50% (n ¼ 2,377) of the study participants were recommended statins. In addition, 589 (12%) were considered for moderate-intensity statins (nondiabetic patients, LDL-C 70 to 189 mg/dl and 10-year ASCVD risk 5% to 7.5%). Baseline characteristics of the study population according to statin eligibility are shown in Table 1 . American Heart Association; CAC ¼ coronary artery calcium. (Figure 4) , and the observed ASCVD risk was above the threshold recommended for treatment (11.7 per 1,000 person-years).
ESTIMATED NUMBER NEEDED TO TREAT TO PREVENT 1 CARDIOVASCULAR EVENT. As shown in Table 3 , applying a 30% relative risk reduction associated with statin therapy, the NNT 10 to prevent an ASCVD in across increasing risk categories among those with ASCVD risk >7.5% (Online Table 1 ). Online Tables 2   and 3 Table 4 ).
INCIDENT CARDIOVASCULAR EVENTS ACCORDING TO CAC SCORES AMONG THE ELDERLY (>75 YEARS)
AND THOSE WITH LOW LDL-C (<70 mg/dl). In our study, among 633 participants >75 years of age who were excluded from analysis, almost all (99%) were recommended for statins, as per ACC/AHA cholesterol management guidelines. Overall, 18% of these elderly participants had CAC ¼ 0, whereas 30% and 52% had CAC between 1 and 100 and CAC >100, respectively.
The respective 10-year event rates across these CAC categories were 6.7 per 1,000, 18.0 per 1,000, and 26.8 per 1,000 person-years.
Among study participants with LDL-C <70 mg/dl who were excluded from the primary analysis, the majority (67%) had CAC ¼ 0, whereas 21% had CAC 1 to 100 and 12% had CAC >100. Overall, the revised risk above the threshold for considering statins was only noted in those with CAC >100 (10-year observed ASCVD event rates for CAC ¼ 0: 2.9 per 1,000 personyears; CAC 1 to 100: 2.6 per 1,000 person-years; and CAC >100: 9.5 per 1,000 person-years). events (19) , such as those with increased atherosclerotic burden, as compared with prior guidelines (20) .
DISCUSSION
However, we are also challenged to treat a significant proportion of patients in low-risk groups, who may derive minimal benefit from these therapies. Accurate risk assessment that can identify these lower-risk subjects can potentially have a profound impact in facilitating appropriate resource allocation and shared decision-making to allow flexible treatment choices.
Our study results suggest that the absence of CAC can potentially overcome these challenges by providing incremental information that may move many people from risk levels that are recommended for treatment to risk levels that are not. This obser- MESA participants with a 10-year ASCVD risk <5%, we noted an extremely low 10-year event rate of 1.6%.
The majority (79%) of these participants have CAC ¼ 0.
The presence of mild CAC (1 to 100) did not result in reclassifying ASCVD risk above 5%, with only 4% of participants with CAC >100 having an observed ASCVD risk above the threshold for statin eligibility.
Although the current guidelines suggest that CAC testing can be considered in selected patients among those with ASCVD risk <5% to inform treatment decision-making, because 25 patients will need to be scanned to influence the treatment decision, its utility in this group is likely to be limited. At the other end of the risk spectrum (estimated 10-year risk >20%), although the presence of CAC ¼ 0 is associated with a much lower observed event rate of 11% than predicted, it may not impact the decision to avoid statins because the risk still remains above the threshold suggested by the guidelines for treatment (1) . By avoiding testing at the extremes of risk (<5% and >20%), 49% of study participants with 10-year ASVCD risk estimates of 5% to 20% can be reclassified by the absence of CAC to a risk threshold below that 
